ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C36H71NO3
CAS番号:
分子量:
565.95
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
製品名
C18:1 Dihydroceramide (d18:0/18:1(9Z)), Avanti Research™ - A Croda Brand 860624P, powder
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 5 mg (860624P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 860624P
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
OC[C@]([H])(NC(CCCCCCC/C=C\CCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC
InChI
1S/C36H71NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,34-35,38-39H,3-16,19-33H2,1-2H3,(H,37,40)/b18-17-/t34-,35+/m0/s1
InChI key
MJQIARGPQMNBGT-WWUCIAQXSA-N
General description
C18:1 Dihydroceramide (d18:0/18:1(9Z)) is a synthetic lipid. Dihydroceramide belongs to the ceramide family. It contains sphinganine, which is devoid of the 4,5-trans-double bond in the sphingoid base backbone.
Application
C18:1 Dihydroceramide (d18:0/18:1(9Z)) has been used as an internal standard to quantify the levels of serum and skeletal muscle lipids extracted from muscle tissue by liquid chromatography-mass spectrometry (MS) analysis. It has also been used as an standard to study its structural characterization by positive-ionization mode 193 nm ultraviolet photodissociation (UVPD)-mass spectrometry/MS.
Biochem/physiol Actions
Dihydroceramide is synthesized by the N-acylation of dihydrosphingosine. It functions as an inactive precursor for ceramide in de-novo sphingolipid synthesis. (Dihydro)-ceramide desaturase catalyzes the conversion of dihydroceramide to ceramide by the addition of C4–5 trans-double bond in the sphingoid backbone. Dihydroceramide has an ability to induce autophagy.
Packaging
5 mL Amber Glass Screw Cap Vial (860624P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
wgk
WGK 3
保管分類
11 - Combustible Solids
Skeletal muscle ceramides and relationship with insulin sensitivity after 2 weeks of simulated sedentary behaviour and recovery in healthy older adults
Reidy PT, et al.
The Journal of Physiology, 596(21), 5217-5236 (2018)
Sexual dimorphism in activation of placental autophagy in obese women with evidence for fetal programming from a placenta-specific mouse model
Muralimanoharan S, et al.
Autophagy, 12(5), 752-769 (2016)
Sribalasubashini Muralimanoharan et al.
Autophagy, 12(5), 752-769 (2016-03-18)
The incidence of maternal obesity and its co-morbidities (diabetes, cardiovascular disease) continues to increase at an alarming rate, with major public health implications. In utero exposure to maternal obesity has been associated with development of cardiovascular and metabolic diseases in